Posted by Michael Wonder on 17 Mar 2022
ICER publishes evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced as a final document an Evidence Report following consideration of public comment.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of trilaciclib (Cosela, G1 Therapeutics) and plinabulin (BeyondSpring Pharmaceuticals) for the prevention of chemotherapy-induced neutropenia and other myelosuppressive effects.
